
Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

FDA action date set for July 26, 2025.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

Less than 15% of women in menopause receive treatment for VMS, suggesting a need a for more education and awareness, according to JoAnn Pinkerton, MD.

Your daily dose of the clinical news you may have missed.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

The addition, based on an approved update to labeling, expands to 4 the recommended vaccination options that health care professionals can offer to pregnant people.

The potential adverse outcomes include asthma, food allergies, cerebral palsy, and cancer, according to a recent systematic review and meta-analysis.

Your daily dose of the clinical news you may have missed.

How does alcohol figure in to American holiday celebrations? We checked with Alcohol.org for this quiz. Are answers what you expect?

Comments on the draft recommendation can be submitted through December 23, 2024.

At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.

The recommendations from WikiGuidelines are the first for UTI prevention, diagnosis, and management in over a decade.

von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.

Your daily dose of the clinical news you may have missed.

The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.